首页> 外文期刊>Trials >Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial
【24h】

Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial

机译:参附注射液治疗冠心病慢性心力衰竭加重的临床评估:一项随机对照试验的研究方案

获取原文
       

摘要

Background Acute exacerbation is a common cause of hospitalization in patients with chronic heart failure, and coronary heart disease is the most common cause. Shenfu injection, a Traditional Chinese Medicine injection, widely used in the adjuvant treatment of patients with acute exacerbation of chronic heart failure, shows some treatment effect in improving the symptoms and the quality of life, but it lacks the rigorous clinical evaluation of research reports. This paper describes the protocol for the clinical assessment of Shenfu injection loading in the treatment of patients with acute exacerbation of chronic heart failure. Methods This protocol adopts the design of a prospective, randomized, multicenter, blind imitation, placebo-controlled trial to assess the efficacy and safety of Shenfu injection loading in the treatment of patients with acute exacerbation of chronic heart failure due to coronary heart disease. The research will be carried out in 12 hospitals in China and is expected to enroll 160 inpatients with acute exacerbation of chronic heart failure due to coronary heart disease ( yang and qi deficiency syndrome). On the basis of the conventional therapy of western medicine, patients will be randomized to either the treatment group (100 ml 5% glucose injection + 50 ml Shenfu injection) or the control group (150 ml 5% glucose injection) for 7 ± 1 days and follow-up for 28 ± 3 days. The primary outcomes are New York Heart Association cardiac function classification and Traditional Chinese Medicine syndromes. The secondary outcomes are left ventricular ejection fraction, brain natriuretic peptide level, Lee’s heart failure score, 6-minute walking distance, and the incidence and readmission rate of cardiovascular events (including the emergency rate due to acute exacerbation of chronic heart failure). Discussion This trial will assess the effect of loading Shenfu injection in the treatment of patients with acute exacerbation of chronic heart failure caused by coronary heart disease ( yang-qi deficiency syndrome) on the symptoms and signs of heart failure, exercise tolerance, and other aspects, and observe its influence on the short-term prognosis with follow-up. The results of the study will provide clinical research evidence for application of Shenfu injection in the treatment. Trial registration This trial was registered on 26 December 2012 at the Chinese Clinical Trials Register (Identifier: ChiCTR-TRC-12002857 ).
机译:背景技术急性加重是慢性心力衰竭患者住院的常见原因,而冠心病是最常见的原因。参附注射液是中药注射剂,广泛用于慢性心力衰竭急性加重患者的辅助治疗,在改善症状和生活质量方面显示出一定的治疗效果,但缺乏严格的临床研究报告。本文介绍了参附注射液治疗慢性心力衰竭急性加重的临床评估方案。方法本方案采用前瞻性,随机,多中心,盲模拟,安慰剂对照试验设计,以评估参附注射液治疗冠心病引起的慢性心力衰竭急性加重的疗效和安全性。这项研究将在中国的12家医院进行,预计将招募160名因冠心病(阳虚气虚综合征)而导致慢性心力衰竭急性加重的住院患者。在西药常规治疗的基础上,将患者随机分为治疗组(100 ml 5%葡萄糖注射液+ 50 ml参附注射液)或对照组(150 ml 5%葡萄糖注射液)治疗7±1天并随访28±3天。主要结果是纽约心脏协会心功能分类和中医证候。次要结果是左心室射血分数,脑钠肽水平,李的心力衰竭评分,6分钟步行距离以及心血管事件的发生率和再入院率(包括由于慢性心力衰竭的急性加重导致的急诊率)。讨论本试验将评估参附注射液治疗由冠心病(阳气不足综合征)引起的慢性心力衰竭急性加重对心力衰竭的症状和体征,运动耐量等方面的作用。并通过随访观察其对短期预后的影响。研究结果将为参附注射液在治疗中的应用提供临床研究证据。试验注册该试验于2012年12月26日在中国临床试验注册中心注册(标识:ChiCTR-TRC-12002857)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号